Overview


According to FutureWise analysis the market for interstitial lung disease treatment in 2023 is US$ 1.6 billion, and is expected to reach US$ 2.69 billion by 2031 at a CAGR of 6.72%.

Interstitial lung disease (ILD) is a general term that encompasses many different lung conditions. The interstitium, a part of the lung's anatomic structure, is affected by lung interstitial diseases. The interstitium consists of a lace-like network of tissues that spans both lungs. The lung's microscopic air sacs (alveoli) are supported by the interstitium. Interstitium contains tiny blood vessels that allow blood and air to exchange gases in the lungs. Lung disease can affect the lungs in three ways. Firstly, the lungs are damaged. Secondly, the interstitium becomes inflamed. At last, fibrosis (scarring) begins in the alveoli (air sacs) and interstitium, resulting in the lung becoming stiff, making breathing difficult. Interstitial lung disease treatment includes a variety of illnesses with diverse causes, treatments, and prognoses. As a result of a persistent sense of shortness of breath, people with interstitial lung disease may have difficulty breathing and moving from place to place. Interstitial lung disease is characterized by scarring of the delicate tissues of the lungs as well as a persistent cough. The progression of interstitial lung disease is slowed by removing environmental triggers that cause the disease.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Interstitial Lung Disease Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Interstitial Lung Disease Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Sumitomo Corporation
  • Johnson and Johnson Private Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Merck KGaA
  • LEO Pharma A/S
  • Cipla Inc.
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Abbott
  • Bayer AG
  • Allergan
  • Merck Sharp and Dohme Corp.
  • Melinta Therapeutics LLC.
  • Tetraphase Pharmaceuticals
  • Paratek Pharmaceuticals, Inc.
  • Nabriva Therapeutics plc.
  • Spero Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Lilly
  • Aurobindo Pharma

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Treatment

  • Antibiotics
  • Corticosteroids
  • Lung Transplant
  • Cytotoxic Drugs
  • Antifibrotics
  • Pulmonary Rehabilitation
  • Oxygen Therapy
  • Others

By Diagnosis

  • Biopsy, Bronchoscopy
  • Lung function test
  • Blood test
  • X-ray
  • CT scan
  • Others

By Dosage

  • Tablet
  • Injection
  • Others

By Route of Administration

  • Oral
  • Intravenous
  • Others

By End-Users

  • Clinic
  • Hospital
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Interstitial Lung Disease Treatment Market By Treatment, By Diagnosis, By Dosage, By Route of Administration, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Interstitial Lung Disease Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Interstitial Lung Disease Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Interstitial Lung Disease Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Interstitial Lung Disease Treatment Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Antibiotics
        2. Corticosteroids
        3. Lung Transplant
        4. Cytotoxic Drugs
        5. Antifibrotics
        6. Pulmonary Rehabilitation
        7. Oxygen Therapy
        8. Others

  • 8.   Interstitial Lung Disease Treatment Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Biopsy, Bronchoscopy
        2. Lung function test
        3. Blood test
        4. X-ray
        5. CT scan
        6. Others

  • 9.   Interstitial Lung Disease Treatment Market, By Dosage Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Tablet
        2. Injection
        3. Others

  • 10.   Interstitial Lung Disease Treatment Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Intravenous
        3. Others

  • 11.   Interstitial Lung Disease Treatment Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Clinic
        2. Hospital
        3. Others

  • 12.   Interstitial Lung Disease Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy

  • 13.   North America Interstitial Lung Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 14.   Latin America Interstitial Lung Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 15.   Europe Interstitial Lung Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 16.   Asia Pacific Interstitial Lung Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 17.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 18.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 19.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Sumitomo Corporation
                 1.1. Company Overview
                 1.2. Product Portfolio
                 1.3. SWOT Analysis
                 1.4. Financial Overview
                 1.5. Strategic Overview
        2. Johnson & Johnson Private Limited
                 2.1. Company Overview
                 2.2. Product Portfolio
                 2.3. SWOT Analysis
                 2.4. Financial Overview
                 2.5. Strategic Overview
        3. Novartis AG
                 3.1. Company Overview
                 3.2. Product Portfolio
                 3.3. SWOT Analysis
                 3.4. Financial Overview
                 3.5. Strategic Overview
        4. Pfizer Inc.
                 4.1. Company Overview
                 4.2. Product Portfolio
                 4.3. SWOT Analysis
                 4.4. Financial Overview
                 4.5. Strategic Overview
        5. Sanofi
                 5.1. Company Overview
                 5.2. Product Portfolio
                 5.3. SWOT Analysis
                 5.4. Financial Overview
                 5.5. Strategic Overview
        6. Merck KGaA
                 6.1. Company Overview
                 6.2. Product Portfolio
                 6.3. SWOT Analysis
                 6.4. Financial Overview
                 6.5. Strategic Overview      
        7. LEO Pharma A/S
                 7.1. Company Overview
                 7.2. Product Portfolio
                 7.3. SWOT Analysis
                 7.4. Financial Overview
                 7.5. Strategic Overview
        8. Cipla Inc.
                 8.1. Company Overview
                 8.2. Product Portfolio
                 8.3. SWOT Analysis
                 8.4. Financial Overview
                 8.5. Strategic Overview
        9. GlaxoSmithKline plc.
                 9.1. Company Overview
                 9.2. Product Portfolio
                 9.3. SWOT Analysis
                 9.4. Financial Overview
                 9.5. Strategic Overview
        10. AstraZeneca
                 10.1. Company Overview
                 10.2. Product Portfolio
                 10.3. SWOT Analysis
                 10.4. Financial Overview
                 10.5. Strategic Overview
        11. Abbott
                 11.1. Company Overview
                 11.2. Product Portfolio
                 11.3. SWOT Analysis
                 11.4. Financial Overview
                 11.5. Strategic Overview      
        12. Bayer AG
                 12.1. Company Overview
                 12.2. Product Portfolio
                 12.3. SWOT Analysis
                 12.4. Financial Overview
                 12.5. Strategic Overview
        13. Allergan
                 13.1. Company Overview
                 13.2. Product Portfolio
                 13.3. SWOT Analysis
                 13.4. Financial Overview
                 13.5. Strategic Overview
        14. Merck Sharp & Dohme Corp.
                 14.1. Company Overview
                 14.2. Product Portfolio
                 14.3. SWOT Analysis
                 14.4. Financial Overview
                 14.5. Strategic Overview
        15. Melinta Therapeutics LLC.
                 15.1. Company Overview
                 15.2. Product Portfolio
                 15.3. SWOT Analysis
                 15.4. Financial Overview
                 15.5. Strategic Overview
        16. Tetraphase Pharmaceuticals
                 16.1. Company Overview
                 16.2. Product Portfolio
                 16.3. SWOT Analysis
                 16.4. Financial Overview
                 16.5. Strategic Overview
        17. Paratek Pharmaceuticals, Inc.
                 17.1. Company Overview
                 17.2. Product Portfolio
                 17.3. SWOT Analysis
                 17.4. Financial Overview
                 17.5. Strategic Overview
        18. Nabriva Therapeutics plc.
                 18.1. Company Overview
                 18.2. Product Portfolio
                 18.3. SWOT Analysis
                 18.4. Financial Overview
                 18.5. Strategic Overview
        19. Spero Therapeutics
                 19.1. Company Overview
                 19.2. Product Portfolio
                 19.3. SWOT Analysis
                 19.4. Financial Overview
                 19.5. Strategic Overview
        20. F. Hoffmann-La Roche Ltd.
                 20.1. Company Overview
                 20.2. Product Portfolio
                 20.3. SWOT Analysis
                 20.4. Financial Overview
                 20.5. Strategic Overview
        21. Mylan N.V.
                 21.1. Company Overview
                 21.2. Product Portfolio
                 21.3. SWOT Analysis
                 21.4. Financial Overview
                 21.5. Strategic Overview
        22. Teva Pharmaceutical Industries Ltd.
                 22.1. Company Overview
                 22.2. Product Portfolio
                 22.3. SWOT Analysis
                 22.4. Financial Overview
         22.5. Strategic Overview
        23. Sun Pharmaceutical Industries Ltd.
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview
        24. Lilly
         24.1. Company Overview
         24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview
        25. Aurobindo Pharma
         25.1. Company Overview
         25.2. Product Portfolio
         25.3. SWOT Analysis
         25.4. Financial Overview
         25.5. Strategic Overview

  • 20.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 21.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients